Patents by Inventor Lucy Vilner

Lucy Vilner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220049217
    Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells am molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described hemin are useful for treating retinal degenerative diseases.
    Type: Application
    Filed: March 29, 2021
    Publication date: February 17, 2022
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20210060062
    Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.
    Type: Application
    Filed: October 9, 2019
    Publication date: March 4, 2021
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20200113938
    Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.
    Type: Application
    Filed: October 9, 2019
    Publication date: April 16, 2020
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Patent number: 10485829
    Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: November 26, 2019
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20190062703
    Abstract: The present invention provides improved methods For producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.
    Type: Application
    Filed: August 27, 2018
    Publication date: February 28, 2019
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Patent number: 10077424
    Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: September 18, 2018
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20150086512
    Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 26, 2015
    Applicant: Advanced Cell Technology, Inc.
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20130149284
    Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.
    Type: Application
    Filed: November 17, 2010
    Publication date: June 13, 2013
    Applicant: Advanced Cell Technlogy, Inc.
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20110274662
    Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.
    Type: Application
    Filed: October 10, 2008
    Publication date: November 10, 2011
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner